PRISM will be accepting submissions for our next screen May 27 – June 13!

DMSO-soluble small molecules (single agent and combination format) and single agent antibodies, ADCs, and growth-inhibiting cytokines will be accepted for our 930 cancer cell line screen.

Miss our team at AACR 2025? Check out our poster presentations!

Publications

Targeting ROS production through inhibition of NADPH oxidases

Reis J, et al. Nature Chemical Biology, 2023
Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors
Lu W, et al. Journal of Medicinal Chemistry, 2023

Mitochondrial metabolism promotes adaptation to proteotoxic stress

Tsvetkov P, et al. Nature Chemical Biology, 2019

The landscape of cancer cell line metabolism

Li H, et al. Nature Medicine, 2019

Conference Posters + Abstracts:
AACR 2025

  • PRISM cancer cell viability profiling enables insights into clinical candidate target selectivity: A case study revealing the most selective PRMT5 inhibitors for cancers with MTAP loss – Abstract | Poster
  • Accelerating the development of biologics: PRISM high throughput screening enables rapid preclinical characterization of antibodies, ADCs and payloads – Abstract | Poster
  • A cellular platform for systematic comparison of RAS inhibitors using PRISM multiplexed screening – AbstractPoster

Conference Abstracts & Posters:

AACR 2023

 

AACR 2022​